Stockscreener 앱 받기
572.51
0.20%
-1.775
전일 마감가:
$574.29
열려 있는:
$574.76
하루 거래량:
114.75K
Relative Volume:
0.24
시가총액:
$25.07B
수익:
$3.18B
순이익/손실:
$1.33B
주가수익비율:
20.52
EPS:
27.9001
순현금흐름:
$1.04B
1주 성능:
-1.27%
1개월 성능:
+9.96%
6개월 성능:
+34.47%
1년 성능:
+95.30%
1일 변동 폭
$569.11
$579.31
1주일 범위
$563.65
$593.65
52주 변동 폭
$272.12
$607.89
유나이티드 테라퓨틱스 Stock (UTHR) Company Profile
명칭
United Therapeutics Corp
전화
(301) 608-9292
주소
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, ZTS, HLN, TEVA
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
571.96 | 25.13B | 3.18B | 1.33B | 1.04B | 27.90 |
TAK
Takeda Pharmaceutical Co Adr
|
16.65 | 53.90B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.65 | 49.70B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.495 | 42.40B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.00 | 36.43B | 17.41B | 1.43B | 1.00B | 1.2182 |
유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Raymond James | Outperform |
| 2025-10-20 | 개시 | Wells Fargo | Underweight |
| 2025-09-26 | 개시 | RBC Capital Mkts | Outperform |
| 2025-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-02-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-12-05 | 개시 | Goldman | Sell |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-20 | 재확인 | BofA Securities | Underperform |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-02-11 | 개시 | BTIG Research | Neutral |
| 2021-07-14 | 업그레이드 | Argus | Hold → Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-06-25 | 재확인 | H.C. Wainwright | Neutral |
| 2020-03-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-27 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-01-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 개시 | BofA/Merrill | Underperform |
| 2019-08-01 | 업그레이드 | Jefferies | Underperform → Hold |
| 2019-08-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-09 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2018-08-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 재확인 | Barclays | Underweight |
| 2018-01-18 | 재개 | Credit Suisse | Underperform |
| 2017-12-27 | 재확인 | Wedbush | Outperform |
| 2017-04-27 | 재확인 | Wedbush | Outperform |
| 2017-03-30 | 개시 | UBS | Sell |
| 2017-03-16 | 개시 | Credit Suisse | Underperform |
모두보기
유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스
United Therapeutics CEO Rothblatt sells $5.42 million in company stock By Investing.com - Investing.com India
United Therapeutics CEO Rothblatt sells $5.42 million in company stock - Investing.com
United Therapeutics Bets on Manufactured Organs for Long-Term Growth - citybiz
United Therapeutics CEO Rothblatt sells $5.57 million in stock By Investing.com - Investing.com India
United Therapeutics CEO Rothblatt sells $5.57 million in stock - Investing.com
United Therapeutics to present research data at heart and lung conference - Investing.com
11 new studies on lung transplants, PH and xenotransplants head to ISHLT - Stock Titan
United Therapeutics Corporation (UTHR) Stock Analysis: A Robust Healthcare Play with a 9.47% Upside - DirectorsTalk Interviews
UTHR PE Ratio & Valuation, Is UTHR Overvalued - Intellectia AI
United Therapeutics (NASDAQ:UTHR) CFO Sells $5,771,800.00 in Stock - MarketBeat
Rothblatt, United Therapeutics CEO, sells $5.48 million in stock - Investing.com
Rothblatt, United Therapeutics CEO, sells $5.48 million in stock By Investing.com - Investing.com Canada
United Therapeutics (NASDAQ:UTHR) Director Christopher Patusky Sells 1,000 Shares - MarketBeat
United Therapeutics (UTHR) director sells 1,000 shares after option exercise - Stock Titan
United Therapeutics (UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan
United Therapeutics (UTHR) CFO sells 10,000 shares after option exercise - Stock Titan
[144] UNITED THERAPEUTICS Corp SEC Filing - Stock Titan
Martine Rothblatt Sells 75 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
Paul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics (UTHR) CEO trades shares under Rule 10b5-1 plan - Stock Titan
United Therapeutics (UTHR) EVP & General Counsel sells 8,300 shares after option exercise - Stock Titan
UNITED THERAPEUTICS CORPORATION (UTHR) - MSN
Rothblatt, United Therapeutics CEO, sells $5.5 million in stock By Investing.com - Investing.com South Africa
Rothblatt, United Therapeutics CEO, sells $5.5 million in stock - Investing.com
United Therapeutics (UTHR) CEO pre-plans 9,500-share option exercise and sale - Stock Titan
CFO of United Therapeutics (UTHR) exercises 10k options, sells 10k shares - Stock Titan
Assetmark Inc. Sells 10,952 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Rothblatt, United Therapeutics CEO, sells $5.4m in UTHR stock - Investing.com UK
Rothblatt, United Therapeutics CEO, sells $5.4m in UTHR stock By Investing.com - Investing.com India
United Therapeutics stock surges 32% in 6 months: Here's why - MSN
UTHR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
United Therapeutics (NASDAQ:UTHR) Stock Rating Upgraded by Raymond James Financial - MarketBeat
UNITED THERAPEUTICS (UTHR) CEO sells 9,500 shares after option exercise under 10b5-1 plan - Stock Titan
Analyst Ratings Update: United Therapeutics (UTHR) Current Price Target Raised | UTHR Stock News - GuruFocus
Rothblatt Martine a of United Therapeutics sells $5.5M in UTHR stock - Investing.com India
Raymond James initiates United Therapeutics stock coverage with outperform rating - Investing.com Australia
Raymond James initiates United Therapeutics stock coverage with outperform rating By Investing.com - Investing.com South Africa
Rothblatt Martine a of United Therapeutics sells $5.5M in UTHR stock By Investing.com - Investing.com South Africa
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
United Therapeutics’ liver device gets FDA regenerative therapy status - Investing.com
Bioengineered liver for acute liver failure gets key FDA designation - Stock Titan
James Edgemond Sells 10,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics (NASDAQ:UTHR) CFO Sells $5,615,000.00 in Stock - MarketBeat
United Therapeutics CFO Edgemond sells $5.6m in UTHR stock By Investing.com - Investing.com Australia
Rothblatt (United Therapeutics) sells $5.3m in UTHR stock By Investing.com - Investing.com Canada
United Therapeutics CFO Edgemond sells $5.6m in UTHR stock - Investing.com
Rothblatt (United Therapeutics) sells $5.3m in UTHR stock - Investing.com
United Therapeutics rises on positive study for cornerstone drug. Why shares could run even higher - MSN
유나이티드 테라퓨틱스 (UTHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
유나이티드 테라퓨틱스 주식 (UTHR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Chairperson & CEO |
Apr 21 '26 |
Sale |
570.42 |
9,500 |
5,419,006 |
40,513 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Apr 20 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
50,013 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Apr 20 '26 |
Sale |
577.83 |
9,500 |
5,489,424 |
40,513 |
| EDGEMOND JAMES | CFO AND TREASURER |
Apr 20 '26 |
Option Exercise |
135.42 |
10,000 |
1,354,200 |
28,876 |
| EDGEMOND JAMES | CFO AND TREASURER |
Apr 20 '26 |
Sale |
577.86 |
10,000 |
5,778,607 |
18,876 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Apr 17 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
50,013 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Apr 17 '26 |
Sale |
586.66 |
9,500 |
5,573,223 |
40,513 |
| PATUSKY CHRISTOPHER | Director |
Apr 17 '26 |
Option Exercise |
101.80 |
1,000 |
101,800 |
2,490 |
| PATUSKY CHRISTOPHER | Director |
Apr 17 '26 |
Sale |
578.88 |
1,000 |
578,880 |
1,490 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Apr 16 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
50,013 |
1.10%
0.88%
자본화:
|
볼륨(24시간):